Mikael Hagstroem has been named as the company’s new CEO.
LabVantage Solutions, a laboratory informatics solutions and services provider, announced on March 25, 2021 that it has named Mikael Hagstroem as its new CEO.
Before taking on his new role, Hagstroem served as CEO and president at MetricStream, an independent provider of governance, risk, and compliance products and solutions; partner at McKinsey & Company and chief operating officer of McKinsey Analytics; and executive vice-president of the SAS Institute and president of SAS International, LabVantage said in a company press release. Additionally, Hagstroem is currently on the board of advisors of the Artificial Intelligence (AI) Forum and has served as chair of the World Economic Forum’s Global Agenda Council on Data-Driven Development, as a member of the executive committee of the US Council for International Business, and as an executive board member of the Atlantic Council.
“[Hagstroem] embodies the sense of purpose and passion required to tackle big goals and the expertise to achieve them,” said Purnendu Chatterjee, chairman of LabVantage Solutions, in the press release. “He is an accomplished business leader who has built innovative data-based enterprises across a range of industries. He is a visionary strategist who understands the transformational potential of advanced technologies and translates them into actionable business initiatives. An inspired leader, [Hagstroem] is committed to accelerating the use of new tools such as analytics and AI to address urgent global problems. We are thrilled to welcome him to LabVantage and excited at the prospect of what we can accomplish together.”
“LabVantage brings the Fourth Industrial Revolution–characterized as a range of new technologies that are fusing the physical, digital, and biological worlds and impacting all disciplines, economies, and industries–to the lab, and I am honored to take the helm,” Hagstroem added in the press release.
Source: LabVantage
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.